Interviews

In an interview with Targeted Oncology Richard Finn, MD, discussed the implications of the LEAP-002 trial.

In an interview with Targeted Oncology, Mazyar Shadman, MD, MPH, discussed what community oncologists should keep in mind when treating patients who are viable for CAR T-cell therapy.

Jonathan E. Rosenberg, MD, discusses what the frontline treatment landscape for metastatic urothelial cancer currently looks like.

Alexander Drilon, MD, discusses what community oncologists should know about testing for  NTRK gene fusions in patients with solid tumors.

Genevieve Boland, MD, PhD, discusses the latest updates to the melanoma treatment landscape.

In an interview with Targeted Oncology, Fred Saad, MD, FRSC, discussed key biomarkers for prostate cancer and findings from a biomarker analysis of the phase 3 PROpel clinical trial.

Srdan Verstovsek, MD, PhD, discusses some of the best practices to try and prevent thrombosis in patients with polycythemia vera.

In an interview with Targeted Oncology, Pierre Gholam, MD, discussed multiple studies currently influencing the hepatocellular carcinoma treatment landscape.

Helen H. Moon, MD, discusses the results of the TIVO-3 trial of tivozanib for patients with recurrent clear cell renal cell carcinoma.

Nathan A. Pennell, MD, PhD, discusses the importance of developing new RET inhibitors for patients with non–small cell lung cancer.

In an interview with Targeted Oncology™, Cyrus M. Khan, MD, discussed new strategies for the treatment of mantle cell lymphoma and needs for the future.

Krzysztof J. Misiukiewicz, MD, discusses when targeted therapy may be used for patients with NTRK-positive thyroid cancer.

In an interview with Targeted Oncology, Matthew Matasar, MD, discusses background information on the ongoing VITALIZE trial of maveropepimut-S in patients with diffuse large B-cell lymphoma.

In an interview with Targeted Oncology during the EMSO Annual Congress, David O’Malley, MD, discussed the phase 1 study of ubamatamab in ovarian cancer.

David S. Hong, MD, discusses what he sees for the future of the NTRK inhibitor larotrectinib.

Adam Weiner, MD, discusses the results of his research on molecular subtyping in prostate cancer.

Edward E. Garon, MS, MS, discusses results from the phase 3 CANOPY-A study of adjuvant canakinumab for the treatment of patients with completely resected non-small cell lung cancer.

Paul A. DiSilvestro discusses the 7-year follow-up results from the phase 3 SOLO1/GOG-3004 trial.

Steven M. Albelda, MD, discusses what he expects the future of chimeric antigen receptor T-cell use in solid tumors to look like.

Ronald S. Go, MD, discusses what community oncologists should know regarding the guidelines on managing patients with histiocytic neoplasms.

Erminia Massarelli, MD, PhD, MS, discusses the efficacy outcomes of the CHRYSALIS trial of amivantamab in patients with non–small cell lung cancer and an EGFR exon 20 insertion.

David Barrington, MD, discusses the next steps for oncologists treating patients with stage 1B, grade 3 endometrial cancer.

Daneng Li, MD, discusses potential second-line options following treatment with bevacizumab plus atezolizumab in patients with hepatocellular carcinoma.

In an interview with Targeted Oncologyy, David S. Hong, MD, discussed an updated analysis of larotrectinib and the data supporting the agent for the treatment of TRK fusion-positive lung tumors.

Valencia D. Thomas, MD, MHCM, discusses the unmet needs which remain in the non-melanoma skin cancer space.

In an interview with Targeted Oncology, David Oubre, MD discussed the use of liquid biopsy to identify prognostic and predictive biomarkers in patients with non–small cell lung cancer. He also explained the results and implications of the INSIGHT study.

Sumanta K. Pal, MD, discusses the safety and efficacy results of the COSMIC-021 clinical trial.

Giuseppe Fallaro, MD, discusses research comparing baseline characteristics of patients with renal cell carcinoma treated with adjuvant pembrolizumab in the real-world setting compared with those treatment treated in the KEYNOTE-564.

Srdan Verstovsek, MD, PhD, discusses why the first ever FDA approved interferon drug ropeginterferon alfa-2b-njft is important for adult patients with polycythemia vera.

Nicolas Gazeau, MS, discusses next steps and unmet needs following a positive retrospective study of anakinra for the management of neurotoxicity and cytokine release syndrome in patients who received chimeric antigen receptor T-cell therapy.